Imaging immunological processes from blood to brain in amyotrophic lateral sclerosis

Sandra Amor | Erik Nutma | Manuel Marzin | Fabiola Puentes

1Department of Pathology, Amsterdam UMC Location VUmc, Amsterdam, the Netherlands
2Department of Neuroscience and Trauma, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK

Correspondence
Sandra Amor, Department of Pathology, Amsterdam UMC, Location VUmc, 1081 HV Amsterdam, the Netherlands.
Email: s.amor@amsterdamumc.nl

Abstract
Neuropathology studies of amyotrophic lateral sclerosis (ALS) and animal models of ALS reveal a strong association between aberrant protein accumulation and motor neurone damage, as well as activated microglia and astrocytes. While the role of neuroinflammation in the pathology of ALS is unclear, imaging studies of the central nervous system (CNS) support the idea that innate immune activation occurs early in disease in both humans and rodent models of ALS. In addition, emerging studies also reveal changes in monocytes, macrophages and lymphocytes in peripheral blood as well as at the neuromuscular junction. To more clearly understand the association of neuroinflammation (innate and adaptive) with disease progression, the use of biomarkers and imaging modalities allow monitoring of immune parameters in the disease process. Such approaches are important for patient stratification, selection and inclusion in clinical trials, as well as to provide readouts of response to therapy. Here, we discuss the different imaging modalities, e.g. magnetic resonance imaging, magnetic resonance spectroscopy and positron emission tomography as well as other approaches, including biomarkers of inflammation in ALS, that aid the understanding of the underlying immune mechanisms associated with motor neurone degeneration in ALS.

KEYWORDS
amyotrophic lateral sclerosis, central nervous system, imaging, innate immune system, microglia, TSPO PET

OTHER ARTICLES PUBLISHED IN THIS REVIEW SERIES
Imaging immune responses in neuroinflammatory diseases. Clinical and Experimental Immunology 2021, 206: 248–250.
Magnetic resonance imaging in neuromyelitis optica spectrum disorder. Clinical and Experimental Immunology 2021, 206: 251–265.
Clinical and neuroimaging findings in MOGAD-MRI and OCT. Clinical and Experimental Immunology 2021, 206: 266–281.
Towards PET imaging of the dynamic phenotypes of microglia. Clinical and Experimental Immunology 2021, 206: 282–300.
Neuroinflammation and immunoregulation in glioblastoma and brain metastases: Recent developments in imaging approaches. Clinical and Experimental Immunology 2021, 206: 314–324.
‘A picture is worth a thousand words’: The use of microscopy for imaging neuroinflammation. Clinical and Experimental Immunology 2021, 206: 325–345.

This is an open access article under the terms of the Creative Commons Attribution NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2021 The Authors. Clinical & Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society for Immunology.
INTRODUCTION

Clinical features of amyotrophic lateral sclerosis (ALS)

While ALS is less prevalent compared to other neurodegenerative diseases, it is undoubtedly one of the most rapidly progressive diseases, with an average survival of 3 years from disease onset. Clinical features, including bulbar onset disease, disease progression rate and the presence of early cognitive changes, have so far been the most effective predictors of survival in ALS [1]. The marked clinical heterogeneity of ALS reflects the loss of motor neuronal system integrity and frontotemporal cortical function [2]. Early neuromuscular junction (NMJ) involvement is also a recognized clinical feature which, in combination with central pathology, leads to a wide spectrum of symptoms and signs including limb and/or bulbar muscle weakness, as well as cognitive and behavioural manifestations [3]. More than 30 genetic mutations have been linked to a small percentage (~20%) of ALS cases [4] of which some of the genetic variants are associated with a more severe disease course [5]. Importantly, novel features of the ALS pathobiology have more recently emerged as determinants of disease progression, notably age and changes of the innate as well as adaptive immunological responses [6].

Similar to other neurodegenerative and neuroinflammatory diseases, an older age of onset is associated with a more severe progression of ALS [7]. Ageing may therefore play a central role in the pathological process underpinning the rate of axonal and neuronal cell loss in ALS. The impact of ageing in ALS is probably due to the gradual accumulation of aberrant protein aggregations with time, but is also likely to be linked to a profound alteration of immunological responses collectively termed ‘inflamming’ [8]. Immunosenescence and the potential loss of immune tolerance during ageing have emerged as potential effects of the reduction of T regulatory cell (Treg) function, which has been reported in ALS individuals with a faster progression of the disease [9]. For example, a recent study has shown that the proteomes of blood mononuclear cells and plasma share a characteristic fingerprint of activation of molecular pathways linked to immune responses and senescence in ALS patients and animal models with a faster progression of the disease [10]. While therapeutic trial design in ALS remains challenging, the availability of novel prognostic and predictive biomarkers that act as surrogates of clinical assessment is likely to aid development of effective therapies for ALS. An important source of molecular targets for biomarkers discovery in ALS is the inflammatory response linked to neurodegeneration, a biological process that can be monitored through the chemical detection of immunological signals in biological fluids and by novel modalities of brain imaging. In addition, structural imaging and the study of diffusivity have yielded information on the anatomical spread of the disease and on structural changes arising from the pathological process. Imaging modalities including biomarkers could thus be used in the clinical setting to not only identify disease progression, but also rule out pathologies mimicking ALS.

Pathology of ALS

The complex genetic landscape of ALS is a strong indication that the ultimate outcome of motor neurone degeneration represents the final common pathway of multiple converging biological alterations. This observation raises the importance of an individualized medicine approach to unravel the pathobiology of the disease, the only potentially successful strategy in the development of biological markers for the a priori clinical stratification in clinical trials [11,12]. The concept of ALS as a non-cell autonomous disorder and the report of a significant disruption of glutamate uptake, as well as of oxidative stress, has evolved towards the game-changing elucidation of the proteinopathy underpinning the pathological process. The identification of genetic defects and of the proteinopathy associated to TAR DNA-binding protein 43 (TDP-43), appearing as ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and ALS, is probably the most substantial step forward in ALS research [12]. As a highly conserved RNA binding protein (RBP), TAR DNA-binding protein 43 (TDP-43) interacts with other RBPs such as hnRNP A/B to regulate all aspects of RNA metabolism. Abnormal TDP-43 migration to the cytosol leads to loss of TDP-43 nuclear function and neuronal death [13]. Loss of TDP-43 in human iPSC-derived cortical-like neurones is associated with stathmin2 (STMN2) mis-splicing, resulting in cryptic exon inclusion and expression of a novel mRNA transcripts [14]. Of note is that RNA binding proteins associated with TDP-43 pathology are potentially responsible for the immunological dysregulation described in the progression of ALS. One line of evidence indicates that immune activation is induced by altered TDP-43 function. Over-expression of TDP-43 in glia and neurones of ALS patients has been shown to drive the pathogenic nuclear factor kappa B (NF-κB) response, resulting in augmented production of proinflammatory factors [15,16]. A recent study showed that TDP-43 induces inflammation in ALS by triggering mitochondrial DNA release into the cytoplasm, inducing activation of the of interferon genes [stimulator of interferon genes (STING)] pathway [17]. Loss of immune tolerance and the development of a chronic proinflammatory environment in the progression of ALS are probably the most obvious outcomes of abnormal protein accumulation and defective clearing mechanisms such as autophagy and proteostasis [18]. The result is the creation...
of a florid inflammatory environment in affected tissues where antigen-presenting cells, microglia, macrophages and astrocytes are active in clearing aggregated and aberrant proteins as well as producing immune mediators that contribute to the inflammatory milieu [19] (Figure 1).

Immunological aspects in ALS

A number of neuroinflammatory changes occur in the pathophysiology of ALS, including glial activation, myeloid and T cell infiltration in the central nervous system (CNS) as well as peripheral immune system activation (Figure 2). Such dysfunctional immune homeostasis has been associated with primary events in ALS pathogenesis, as well as disease progression and disease stage [20]. In support of this are the early presymptomatic changes in animal models of ALS in which various pathological and clinical signs are observed, characterized by the activation of astrocytes, microglia and inflammatory molecules [21].

In autopsy studies in humans, indicators of immune activation in the CNS in ALS include the up-regulation of Toll-like receptor (TLR)-4 signalling genes [22] and the persistent activation and nuclear translocation of transcription-3 [signal transducer and activator of transcription 3 (STAT-3)] in microglia [23]. Other glial proteins associated with the progression of the disease include increased glial fibrillary acidic protein (GFAP) and connexin expression in astrocytes and CD68 in microglia [24–26]. Furthermore, increased expression of small heat shock proteins (HSPBs), predominantly in astrocytes in ALS, have been associated with disease duration [27] indicating reactive changes in response to tissue damage such as tau expression in motor neurones (Table 1).

Pathology studies of the CNS in human ALS reveal infiltration of monocytes/macrophages and T cells [28], as well as immunoglobulin and complement deposits associated with motor neurone destruction. Similarly, the presence of activated glia and T cell subpopulations in the brain parenchyma have been linked to motor neurone damage [29]. Also, CD34+ cells co-expressing the myeloid marker CD11b, which represents a subset of microglia, are observed adjacent to degenerating motor neurones in autopsied spinal cord from sporadic ALS subjects, but such cells are absent in control subjects [30] (Table 1).

Peripherally, the expansion of proinflammatory T helper type 1 (Th1)/Th17 cells and the decrease of anti-inflammatory Th2 and Tregs correlate with the presence of activated microglia [31] and ALS severity and progression [32]. In contrast, low levels of Tregs expressing forkhead box protein 3 (FoxP3), as well as reduced mRNA levels of transforming growth factor (TGF)-β, interleukin (IL)-4 and GATA binding protein 3 (GATA3) in T cells from ALS patients, predict reduced survival and rapid progression of disease [33].
In line with these studies, the suppressive dysfunction of T\(_{reg}\) is most marked in fast-progressing ALS patients compared to slow-progressing patients and healthy donors [9]. These observations have been extended in clinical trials aimed to increase the suppressive effect of regulatory T lymphocytes. In support of this, autologous infusions of T\(_{reg}\) into patients at early and later stages of ALS have been shown to be safe, and importantly reported to slow the progression rate of disease [34]. Emerging data have also linked myeloid cell signatures to clinical features of ALS [35]. For example, within the peripheral motor system, the frequency of myeloid cell populations and expression of CD14 and human leucocyte antigen D-related (HLA-DR) are associated with bulbar symptoms and clinical severity [36]. Furthermore, genetic variants of triggering receptors expressed on myeloid cells (Trem2) expressed on myeloid cells have been associated with increased risk of ALS [37]. However, this finding remains controversial, as specific variants can influence the effect of Trem2 on inflammation, as reported in other studies [38]. The presence of autoantibodies directed to neuromuscular junction (NMJ) antigens have also been detected in ALS as well as other disorders of neuromuscular transmission, showing upper and lower motor neurone involvement [39–41]. For example, antibodies to low-density lipoprotein-related receptor protein 4 (LRP4) are involved in neurological symptoms affecting LRP4-containing tissues.
and are found more frequently in ALS than in myasthenia gravis MG [39,41,42]. Whether LR4 antibodies may have a pathogenic activity in ALS in the denervation process is unclear [41]. At the NMJ, LR4, agrin proteins, muscle-specific kinase (MuSK) and acetylcholine receptors (AChR clustering), which make up the synapses between spinal motor neurons and the skeletal muscle, are the main targets of the immune system [43,44] (Figure 2, Table 1).

In ALS, peripheral local immune responses along the degenerating motor axons in sciatic nerves and skeletal muscle are observed [45]. Additionally, activated monocytes, mast cells, neutrophils and inflammatory mediators are involved in the immune cell recruitment in the neuromuscular compartment [35,46].

In summary, inflammation in the periphery and also the CNS are constant features of both early and late stages of ALS. Immune cells, activation markers and molecules related to the disease pathology and the application of positron emission tomography (PET) and magnetic resonance (MR) imaging to study physiological changes of target tissues in ALS are illustrated and summarized in Figure 2 and Table 1.

**Animal models of ALS**

The most common ALS-associated mutations occur in SOD1, TARDBP, FUS and C9ORF72, and thus genetically modified animals expressing mutations of these genes have been developed to understand pathological mechanisms leading to neuronal death and develop therapeutic strategies [47,48]. Local glial activation, T cell infiltration and immunoglobulin deposition in the CNS, as well as systemic immune system activation in animal models and ALS patients, support the concept that immunological pathways contribute to disease progression. To identify immune biomarkers of disease, imaging modalities have been applied to monitor these pathways during disease.

While imaging of ALS patients presents fewer problems than imaging small animals, linking imaging studies to pathological features of ALS in humans is difficult, and is limited to post-mortem MR imaging (MRI) and pathology studies. By contrast, models including bi- and triple transgenic mice lend themselves to the study of specific immune factors. As an example, monocyte chemoattractant protein 1 (MCP1) and C-C chemokine receptor type 2 (CCR2) genetically labelled with monomeric red fluorescent protein-1 (mRFP) and enhanced green fluorescent protein (eGFP) [49] crossed into the human superoxide dismutase 1 (hSOD1G93A) mouse has allowed visualization of the timing and the extent of innate immune response in the CNS during disease initiation and progression [49]. Similarly, regional neurochemistry alterations have been examined in SOD mice using localized in-vivo magnetic resonance spectroscopy (MRS), revealing changes in creatine, N-acetylaspartate (NAA), glutamate, glutamine, γ-aminobutyric acid (GABA) and myo-inositol [50]. Mouse models also lend themselves to in-vivo PET imaging studies to study synaptic glutamatergic function [18F]FPEB ([18F]3-fluoro-5-[2-pyridylethynyl]-benzonitrile) [51] and inflammatory response using [11C]PBR28 (peripheral benzodiazepine receptor ligand). While neuroimmunological processes in animal models of ALS can be easily visualized, the development of transgenic mice in which immune markers are tagged using fluorescent probes, and the availability of in-vivo imaging, has expanded the imaging possibilities in the ALS field. For example, multi-photon in-vivo microscopy (MPM), in which tissue localized deeper within the organism is accessed through ‘imaging windows’ similar to one-photon microscopy,
could be applied to ALS models. Sekiguchi et al. successfully implemented MPM to image calcium responses of astrocytes in murine spinal cords [52]. Such applications in suitable transgenic mice models of ALS, as discussed above, could allow for detailed analysis of the disease process in time in in-vivo models. An alternative animal
model for live imaging in neurodegenerative diseases is the zebrafish. Because of its translucency there is no need for invasive surgical procedures such as implanting imaging windows. Furthermore, several genes associated with ALS, e.g. SOD1, are highly conserved in the zebrafish [53]. In addition, many transgenic zebrafish lines in which fluorescent reporters have been inserted are suitable for ALS research. These include Tg(spi1b:GAL4,UAS:TagRFP) and Tg(mnx1-GFP), fluorescent proteins specific to glial cells and motor neurones, respectively [54]. Linking these approaches in animal models to the conventional imaging modalities in humans, as discussed below, will be critical to more clearly understand the disease process in humans.

IMAGING MODALITIES

Several imaging modalities have been used to monitor neuroinflammation and pathological changes in ALS and experimental animal models of ALS [46]. One approach is PET imaging, which has the advantage of being able to interrogate various disease mechanisms using specific molecular ligands to directly study the CNS, peripheral nervous system (PNS) or neuromuscular junction [55]. Furthermore, PET allows direct visualization of neuroinflammation in early stages of disease as well as recurrent analysis to monitor disease progression. Importantly, this approach lends itself to study the efficacy of therapies targeting molecular pathways that can be visualized by specific ligands [55]. PET imaging may thus serve as a marker of disease progression or a prognostic or predictive biomarker, while allowing a detailed analysis of molecular alterations key to the pathogenesis of ALS, such as cerebral blood flow, glucose metabolism, neuroinflammation, neuronal dysfunction and oxidative stress [56]. Most studies utilizing PET for ALS use 18F-fluorodeoxyglucose (FDG), a radiotracer that only detects glucose metabolism but does not directly detect inflammatory processes in the CNS. By contrast, translocator protein (TSPO) PET imaging is a promising molecular imaging technique that represents a multi-cellular neuroinflammatory reaction, with a potential use as pharmacodynamic biomarker for ALS therapies [57,58]. TSPO is expressed on microglia and astrocytes in the CNS under neuroinflammatory conditions, and TSPO-targeting PET detects high densities of microglial activity [59]. Early studies have used first-generation TSPO ligands [11C]-PK11195 (1-[2-chlorophenyl]-N-[1-methyl-propyl]-3-i soquinoline carboxamide) and [18F]-DPA-714 (N,N-diethyl-2-[4-(2-fluoroethoxy)phenyl]-5,7-dimethlypyrazolo[1,5-a] pyrimidine-3-acetamide), while more recent studies use second-generation TSPO tracers [11C]-PBR28 (N-[2-methoxyphenyl]methyl]-N-(2-phenoxophenyl)acetamid), which have improved uptake and binding affinity compared to older tracers [60]. A higher TSPO PET signal was found in motor cortex, supplementary motor and temporal cortex in ALS patients with bulbar onset compared to healthy controls using [18F]-DPA-714 [61]. A study using [11C]-PK11195 showed increases in binding in motor cortex, pons, frontal lobe regions and the thalamus in ALS patients compared to healthy controls, regardless of bulbar or limb onset [62].

More recent studies utilizing [11C]-PBR28 report increased binding of TSPO PET in the motor cortex, but also in upper regions of the corticospinal tracts [63–65]. More specifically, increased binding was found in precentral gyri for limb-onset ALS patients and in the brain stem for bulbar-onset ALS patients, indicating that glial activation is present in clinically relevant neuroanatomical areas [63,64] and providing an atlas of the disease neuropathology with a close relationship to the clinical phenotype. Correlating altered PET binding with MRI has shown that increased binding in the precentral gyri was associated with cortical thinning, reduced fractional anisotropy (FA) and higher diffusivity [66,67]. However, no changes were found in [11C]-PBR28 uptake during 6 months of disease progression. While TSPO PET originally was initially thought to reflect pathogenic microglia activation, a recent study identified that TSPO PET reflects microglial density rather than the microglial activation state in multiple sclerosis (MS) [68]. Overall, PET studies have found similar affected regions in ALS patients (motor cortex and the upper corticospinal tracts), and there is some evidence that astrocytes are also affected in the white matter and the pons of ALS patients showing increased binding of [11C]-DED (deuterium-L-deprenyl), which binds to the monoamine oxidase B (MAO-B) present on mitochondria of reactive astrocytes [57]. Furthermore, while there is no lack of PET studies in ALS [56] most do not focus upon glial cells and have limitations that restrict the ability to draw strong conclusions about the immunopathology in ALS. In addition, few studies involve large sample sizes or follow their subjects longitudinally.

Another approach is MRI, frequently used to identify novel so-called ‘dry biomarkers’ which, together with the use of functional scales, task performance and electrophysiology, has become an established field of investigation in ALS [69]. The use of MRI is one of the most relevant tools to address the lack of understanding of the origin and progression of the disease, with most models based on the assumption of a disease originating and propagating from the cortex or the spinal cord and later developing into a diffused neuromuscular disease [70]. Technical limitations, such as the lack of homogeneity due to the proximity of the spinal cord to bone, air and soft tissue, as well as the cerebrospinal fluid (CSF) flow, have limited the ability of MRI to detect changes in the spinal cord in ALS [71]. Furthermore, imaging of the spine is not only limited by motion of the CSF but also physiological motion due to breathing [71,72]. MRI has clear value in the evaluation of structural changes, and can be applied to
retrieve information on a range of pathological processes and their anatomical distribution.

MRI techniques include voxel-based morphometry (VBM), diffusion tensor imaging (DTI), magnetic resonance spectroscopy (MRS) and other iron-sensitive sequences, including T2, susceptibility weighted imaging (SWI) and functional MRI (fMRI). These methodologies make it possible to extend the investigation from structural into functional changes. For example, MR structural imaging has highlighted volumetric and cortical changes in the precentral gyrus and somatosensory areas, changes associated with the progression of ALS, although the degree of volume and substance loss has not always correlated with functional parameters of disease progression [73]. Together with structural changes and analysis of connectivity of different CNS regions, a deeper insight into the loss of function in key areas of ALS pathology has come from the use of DTI, allowing the identification of low fraction anisotropy along the corticospinal tracts in patients with ALS [74]. Such studies, e.g. diffusion tensor MRI, have also been applied in a mouse model of ALS to evaluate axonal injuries across different axonal tracts [75].

To more clearly correlate imaging studies with pathology, combined post-mortem T1 sequence and histological assessment in ALS patients have been applied. These studies show changes between cortical grey matter and subcortical white matter in the motor cortex, in somatosensory areas and in the primary visual cortex. In part, these changes are attributed to neurone loss but also to increased numbers of astrocytes correlating with findings from PET imaging [57,76,77]. MR studies in ALS have also revealed a link between tissue inflammation and iron deposition in the motor cortex in ALS patients, as well as animal models. Motor cortex hypointensity on MRI images in ALS is associated with increased iron accumulation by microglia [78], although it is unclear how iron contributes to the disease process [79]. Further imaging studies, such as proton magnetic resonance spectroscopy, have enabled the detection of aspartate metabolites, choline, the glial marker myoinositol, amino acids and compounds related to cellular bioenergetic and oxidative status. In ALS such metabolites, including glutamate, N-acetyl aspartate and gamma aminobutyric acid present in the supplementary motor area, have been suggested to act as a surrogate biomarker for ALS [78,80]. A novel imaging technique, chemical exchange saturation transfer (CEST), provides high-resolution and sensitivity to image-specific metabolites and was already shown to differentiate ALS by reduced CEST signal intensity in the motor cortex [81].

In summary, the use of PET and MR imaging has revealed that TSPO and myoinositol, a spectroscopic marker for glial activity, are increased in the motor cortex of ALS patients and represent promising biomarkers of neuroinflammation [56,81–84].

Biomaterial fluid biomarkers

A number of potential biomarkers relevant to both CNS and/or neuromuscular pathology ALS include biological fluid-based neurochemical biomarkers, neuroimaging techniques, electrophysiological parameters, electrical impedance myography and clinical features that are captured by a number of functional rating scales [85]. The development of new highly specific imaging approaches for visualizing immune activation will be critical for the integration of imaging and biofluid-based inflammatory biomarkers.

Studies of CSF, blood, urine and saliva in ALS have facilitated the identification and quantification of diseasespecific molecules that show higher clinical utility when analysed in combination. For example, levels of neurofilament proteins (NF) present in CSF and blood samples have been extensively characterized as diagnostic and prognostic markers of disease [86–89] and thus have potential utility as pharmacodynamic biomarkers [86], supporting their potential implementation into clinical practice. For example, a recent longitudinal study showed a panel of blood markers of neuronal integrity, e.g. NF light chain, phosphorylated NF heavy chain, DNA oxidation, lipid peroxidation, IL-6 and iron status, have a high predictive value of ALS progression [90], whereas gene expression of copper chaperone for superoxide dismutase (CCS) and genes linked to mitochondrial respiration are associated with survival [91]. Other CSF and blood-based biomarkers, whose increased levels are associated with the degree of neuronal damage, include circulating microRNAs, inflammatory markers (IL-8, IL-5, IL-10, IL-15 and IL-2), granulocyte–macrophage colony-stimulating factor (GM-CSF), TDP-43 and metabolites (glutamate and lysine), and SOD1 proteins in familial and sporadic disease [92,93]. Recent data also indicate that levels of chitinase expressed in activated astrocytes reflect neuroinflammation in both genetic and sporadic forms of ALS [94,95]. This is supported by the finding that a gradual rise in CSF levels of chitinase correlates with the presymptomatic and early symptomatic phases of ALS, suggesting its potential as a target of immune therapeutic interventions [96]. Despite the finding that several markers such as NF-L in the CSF levels differentiate ALS from inflammatory peripheral neuropathies, urinary p75 neurotrophin receptor extracellular domain (p75NTRECD) is currently the only biological fluid-based biomarker of disease progression [97].

Given the substantial heterogeneity of the disease and variability in progression rates in ALS, identification of biological fluid biomarkers for the clinical stratification of the disease remains challenging and is currently not strongly linked with local pathology. In light of this, electrophysiological biomarkers such as nerve conduction study parameters and needle electromyography, that
measures the intrinsic electrical activity of muscle fibres, together with the clinical examination, are the main approach in the diagnosis of ALS [98]. In addition, the strong link between ALS disease progression and NMJ dysfunction suggests that biomarkers of NMJ damage such as SMAD proteins elevated in ALS muscle or muscle-specific microRNAs could potentially serve as markers of disease progression or regression [99,100]. In line with this, markers that reflect muscle atrophy and denervation have been associated with poor prognosis and a short survival time in ALS patients [101].

FUTURE PERSPECTIVES

The development of imaging approaches to visualize disease progression, as well as to examine and determine pathological mechanisms operating in disease, will continue to be key to discriminate ALS from non-ALS diseases as well as segregate subgroups of ALS patients. Important considerations when applying imaging modalities to distinguish different forms of ALS, disease progression or response to therapy include the size of cohorts used, as well as the appropriate control cohorts. For example, small or heterogenous ALS cohorts or inadequately controlled cohorts are probably reasons for the inconsistent findings in published studies. The emerging technology in ultra-high field and resolution functional MRI and time-of-flight PET/MRI offers new possibilities in human imaging. Advances in imaging performance with increased sensitivity and specificity will enable higher spatial and temporal resolution and detection of targets with low endogenous expression.

ACKNOWLEDGEMENTS

There was no funding for this review. The authors thank Professor Andrea Malaspina for helpful comments and suggestions on the review. We also thank Dr M. Jacob, Dr J. Hooker and Dr M. M. Makary for the PET imaging of an ALS patient showing high uptake of PBR-28.

CONFLICTS OF INTEREST

All authors declare no conflicts of interest.

AUTHOR CONTRIBUTIONS

All authors contributed equally and all approved the final version of the manuscript.

DATA AVAILABILITY STATEMENT

Data are freely available upon reasonable request.

ORCID

Sandra Amor https://orcid.org/0000-0001-6169-9845

REFERENCES

1. Chiò A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10:310–23.
2. Achi EY, Rudnicki SA. ALS and frontotemporal dysfunction: a review. Neurol Res Int. 2012;2012:806306.
3. Westeneng H-J, Debray TPA, Vissel AE, van Eijk RPA, Rooney JPK, Calvo A, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17:423–33.
4. Connolly O, Le Gall L, McCluskey G, Donaghy CG, Duddy WJ, Duguez S. A systematic review of genotype-phenotype correlation across cohorts having causal mutations of different genes in ALS. J Pers Med. 2020;10:58.
5. Mejzini R, Flynn LL, Pitout IL, Fletcher S, Wilton SD, Akkari PA. ALS genetics, mechanisms, and therapeutics: where are we now? Front Neurosci. 2019;13:1310.
6. Malaspina A, Puentes F, Amor S. Disease origin and progression in amyotrophic lateral sclerosis: an immunology perspective. Int Immunol. 2015;27:117–29.
7. Niccoli T, Partridge L, Isaacs AM. Ageing as a risk factor for ALS/FTD. Hum Mol Genet. 2017;26(R2):R105–R13.
8. Minciullo PL, Catalano A, Mandraffino G, Casciaro M, Crucitti A, Maltese G, et al. Inflammaging and anti-inflammaging: the role of cytokines in extreme longevity. Arch Immunol Ther Exp (Warsz). 2016;64:111–26.
9. Beers DR, Zhao W, Wang J, Zhang X, Wen S, Neal D, et al. ALS patients’ regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity. JCI Insight. 2017;2:e89530.
10. Zubiri I, Lombardi V, Bremang M, Mitra V, Nardo G, Adiutori R, et al. Tissue-enhanced plasma proteome analysis for disease stratification in amyotrophic lateral sclerosis. Mol Neurodegener. 2018;13:60.
11. van Eijk RPA, Kliest T, van den Berg LH. Current trends in the clinical trial landscape for amyotrophic lateral sclerosis. Curr Opin Neurol. 2020;33:655–61.
12. Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351:602–11.
13. Iguchi Y, Katsuno M, Niwa J-I, Takagi S, Ishigaki S, Ikenaka K, et al. Loss of TDP-43 causes age-dependent progressive motor neuron degeneration. Brain. 2013;136(Pt 5):1371–82.
14. Melamed Z, López-Erauskin J, Baughn MW, Zhang O, Drenner K, Sun Y, et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat Neurosci. 2019;22:180–90.
15. Swarup V, Phaneuf D, Dupre N, Petri S, Strong M, Kriz J, et al. Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor kappaB-mediated pathogenic pathways. J Exp Med. 2011;208:2429–47.
16. Bright F, Chan G, van Hummel A, Ittner LM, Ke YD. TDP-43 and inflammation: implications for amyotrophic lateral sclerosis and frontotemporal dementia. Int J Mol Sci. 2021;22:7781.
17. Lee JD, Woodruff TM. TDP-43 Puts the STING in ALS. Trends Neurosci. 2021;44:81–2.
18. Vicencio E, Beltran S, Labrador L, Manque P, Nassif M, Woehlbier U. Implications of selective autophagy dysfunction for ALS pathology. Cells. 2020;9:381.

19. Clarke BE, Patani R. The microglial component of amyotrophic lateral sclerosis. Brain. 2020;143:3526–39.

20. Béland L-C, Markovinovic A, Jakovac H, De Marchi F, Blic E, Mazzini L, et al. Immunity in amyotrophic lateral sclerosis: blurred lines between excessive inflammation and inefficient immune responses. Brain Commun. 2020;2:fcaa124.

21. Keller AF, Gravel M, Kriz J. Treatment with minocycline after disease onset alters astrocyte reactivity and increases microgliosis in SOD1 mutant mice. Exp Neurol. 2011;228:69–79.

22. Zhang R, Hadlock KG, Do H, Yu S, Honrada R, Champion S, et al. Gene expression profiling in peripheral blood mononuclear cells from patients with sporadic amyotrophic lateral sclerosis (sALS). J Neuroimmunol. 2011;230:114–23.

23. Shibata N, Kakita A, Takahashi H, Ibara Y, Nobukuni K, Fujimura H, et al. Activation of signal transducer and activator of transcription-3 in the spinal cord of sporadic amyotrophic lateral sclerosis patients. Neurodegener Dis. 2009;6:118–26.

24. Brettschneider J, Toledo JB, Van Deerlin VM, Elman L, McCluskey L, Lee V-Y, et al. Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis. PLOS ONE. 2012;7:e39216.

25. Gaur N, Perner C, Witte OW, Grosskreutz J. The chitinases as biomarkers for amyotrophic lateral sclerosis: signals from the CNS and beyond. Front Neurol. 2020;11:377.

26. Almad AA, Doreswamy A, Gross SK, Richard J-P, Huo Y, Haughey N, et al. Connexin 43 in astrocytes contributes to motor neuron toxicity in amyotrophic lateral sclerosis. Glia. 2016;64:1154–69.

27. Gorter RP, Stephenson J, Nutma E, Anink J, Jonge JC, Baron W, et al. Rapidly progressive amyotrophic lateral sclerosis is associated with microglial reactivity and small heat shock protein expression in reactive astrocytes. Neuropathol Appl Neurobiol. 2019;45:459–75.

28. Liu Z, Cheng XI, Zhong S, Zhang X, Liu C, Liu F, et al. Peripheral and central nervous system immune response crosstalk in amyotrophic lateral sclerosis. Front Neuosci. 2020;14:575.

29. Holmoy T. T cells in amyotrophic lateral sclerosis. Eur J Neurol. 2008;15:360–6.

30. Kovacs M, Trias E, Varela V, Ibarburu S, Beckman JS, Moura IC, et al. CD34 identifies a subset of proliferating microglial cells associated with degenerating motor neurons in ALS. Int J Mol Sci. 2019;20:3880.

31. Zhao W, Beers DR, Appel SH. Immune-mediated mechanisms in the pathop progression of amyotrophic lateral sclerosis. J Neuroimmunopharm. 2013;8:888–99.

32. Jin M, Gunther R, Akgun K, Hermann A, Ziemssen T. Peripheral proinflammatory Th1/Th17 immune cell shift is linked to disease severity in amyotrophic lateral sclerosis. Sci Rep. 2020;10:5941.

33. Henkel JS, Beers DR, Wen S, Rivera AL, Toennis KM, Appel JE, et al. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med. 2013;5:64–79.

34. Thonhoff JR, Beers DR, Zhao W, Pleitez M, Simpson EP, Berry JD, et al. Expanded autologous regulatory T-lymphocyte infusions in ALS: A phase I, first-in-human study. Neurol Neuroimmunol Neuroinflamm. 2018;5:e465.

35. McGill RB, Steyn FJ, Ngo ST, Thorpe KA, Heggie S, Ruitenbeek MJ, et al. Monocytes and neutrophils are associated with clinical features in amyotrophic lateral sclerosis. Brain Commun. 2020;2:fcaa103.

36. McCombe PA, Lee JD, Woodruff TM, Henderson RD. The peripheral immune system and amyotrophic lateral sclerosis. Front Neurol. 2020;11:279.

37. Cipollina G, Davari Serej A, Di Nolfi G, Gazzano A, Marsala A, Spatafora MG, et al. Heterogeneity of neuroinflammatory responses in amyotrophic lateral sclerosis: a challenge or an opportunity? Int J Mol Sci. 2020;21:7923.

38. Siokas V, Aloizou A-M, Liampas I, Tsouris Z, Mentis A-F, Nasios G, et al. Lack of association between TREM2 rs75932628 variant and amyotrophic lateral sclerosis. Mol Biol Rep. 2021;48:2601–10.

39. Rivner MH, Liu S, Quares B, Fleener B, Shen C, Pan J, et al. Agrin and low-density lipoprotein-related receptor protein 4 antibodies in amyotrophic lateral sclerosis patients. Muscle Nerve. 2017;55:430–2.

40. Cao M, Konczczyn I, Vincent A. Myasthenia gravis with antibodies against muscle specific kinase: an update on clinical features. Pathophysiology and treatment. Front Mol Neurosci. 2020;13:159.

41. Tzartos J, Zisimopoulou P, Tsonis A, Evangelakou P, Rentzos M, Karandreas N, et al. LRP4 antibodies are frequent in serum and CSF from amyotrophic lateral sclerosis patients (S34.004). Neurology. 2015;84.

42. Tzartos JS, Zisimopoulou P, Rentzos M, Karandreas N, Zouvelou V, Evangelakou P, et al. LRP4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients. Ann Clin Transl Neurol. 2014;1:80–7.

43. Mehanna R, Patton EL Jr, Phan CL, Harati Y. Amyotrophic lateral sclerosis with positive anti-acetylcholine receptor antibodies. Case report and review of the literature. J Clin Neurosci. 2012;14:82–5.

44. Dai H, Cui L, Guan Y, Liu M, Li X, Huang Y, et al. Amyotrophic lateral sclerosis and myasthenia gravis overlap syndrome: a review of two cases and the associated literature. Front Neurol. 2017;8:218.

45. Trias E, Kovacs M, King PH, Si Y, Kwon Y, Varela V, et al. Schwann cells orchestrate peripheral nerve inflammation through the expression of CSF1, IL-34, and SCF in amyotrophic lateral sclerosis. Glia. 2020;68:1165–81.

46. Trias E, King PH, Si Y, Kwon Y, Varela V, Ibarburu S, et al. Mast cells and neutrophils mediate peripheral motor pathway degeneration in ALS. JCI Insight. 2018;3.

47. Chia R, Chio A, Traynor BJ. Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol. 2018;17:94–102.

48. Stephenson J, Amor S. Modelling amyotrophic lateral sclerosis in mice. Drug Discov Today Dis Models. 2017;25–26:35–44.

49. Jara JH, Genç B, Stanford MJ, Pytel P, Roos RP, Weintraub S, et al. Evidence for an early innate immune response in the motor cortex of ALS. J Neuroinflamm. 2017;14:129.

50. Weerasekera A, Sima DM, Dresseslaers T, Van Hulvel S, Van Damme P, Himmelreich U. Non-invasive assessment of disease progression and neuroprotective effects of dietary coconut oil supplementation in the ALS SOD1(G93A) mouse model: A (1) H-magnetic resonance spectroscopic study. Neuroimage Clin. 2018;20:1092–105.
51. Wang QJ, Tuckmantel W, Zhu A, Pellegrino D, Brownell AL. Synthesis and preliminary biological evaluation of 3-[(18)F][fluoro-5-(2-pyridinylethynyl)]benzonitrile as a PET radiotracer for imaging metabotropic glutamate receptor subtype 5. Synapse. 2007;61:951–61.

52. Sekiguchi KJ, Shekhtmeyster P, Merten K, Arena A, Cook D, Hoffman E, et al. Imaging large-scale cellular activity in spinal cord of freely behaving mice. Nat Commun. 2016;7:11450.

53. Da Costa MM, Allen CE, Higginbottom A, Ramesh T, Shaw PJ, McDermott CJ. A new zebrafish model produced by TILLING of SOD1-related amyotrophic lateral sclerosis replicates key features of the disease and represents a tool for in vivo therapeutic screening. Dis Model Mech. 2014;7:73–81.

54. Morrice JR, Gregory-Evans CY, Shaw CA. Modeling Environmentally-Induced Motor Neuron Degeneration in Zebrafish. Sci Rep. 2018;8:4890.

55. Kreisl WC, Kim MJ, Coughlin JM, Henter ID, Owen DR, Innis RB. PET imaging of neuroinflammation in neurological disorders. Lancet Neurol. 2020;19:940–50.

56. Chew S, Atassi N. Positron emission tomography molecular imaging biomarkers for amyotrophic lateral sclerosis. Front Neurol. 2019;10:135.

57. Johansson A, Engler H, Blomquist G, Scott B, Wall A, Aquilonius S-M, et al. Evidence for astrocytosis in ALS demonstrated by [11C](L)-deprenyl-D2 PET. J Neurol Sci. 2007;255:17–22.

58. Ghadery C, Best LA, Pavese N, Tai YF, Strafella AP. PET evaluation of microglial activation in non-neurodegenerative brain diseases. Curr Neurol Neurosci Rep. 2019;19:38.

59. Nutma E, Ceyzériat K, Amor S, Tsartsalis S, Millet P, Owen DR, et al. Cellular sources of TSPO expression in healthy and diseased brain. Eur J Nucl Med Mol Imaging. 2021.

60. Kreisl WC, Fujita M, Fujimura Y, Kimura N, Jenko KJ, Kannan P, et al. Comparison of [11C]-(R)-PK 11195 and [11C] PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: implications for positron emission tomographic imaging of this inflammation biomarker. NeuroImage. 2010;49:2924–32.

61. Corcia P, Tauber C, Vercoullie J, Arlicot N, Prunier C, Cernasov P, et al. Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [(11) C]-PBR28. Neuroimage Clin. 2015;7:409–14.

62. Turner MR, Cagnin A, Turkheimer FE, Miller C, Shaw CE, Brooks DJ, et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis. 2004;15:601–9.

63. Zürcher NR, Loggia ML, Lawson R, Chonde DB, Izquierdo-Garcia D, Yasek JE, et al. Increased microstructural abnormalities in amyotrophic lateral sclerosis: an in vivo [11C] PBR28 PET study. Magn Reson Imaging. 2016;41:665–75.

64. Albrecht DS, Normandin MD, Shecherbinin S, Wooten DW, Schwarz AJ, Zürcher NR, et al. Pseudoreference Regions for Glial Imaging with [(11)C]-PBR28: Investigation in 2 Clinical Cohorts. J Nucl Med. 2018;59:107–14.

65. Alshikho MJ, Zürcher NR, Loggia ML, Cernasov P, Reynolds B, Pijanowski O, et al. Integrated magnetic resonance imaging and [(11) C]-PBR28 positron emission tomographic imaging in amyotrophic lateral sclerosis. Ann Neurol. 2018;83:1186–97.

66. Alshikho MJ, Zürcher NR, Loggia ML, Cernasov P, Chonde DB, Izquierdo Garcia D, et al. Glial activation colocalizes with structural abnormalities in amyotrophic lateral sclerosis. Neurology. 2016;87:2554–61.

67. Nutma E, Gebro E, Marzin MC, van der Valk P, Matthews PM, Owen DR, et al. Activated microglia do not increase 18 kDa translocator protein (TSPO) expression in the multiple sclerosis brain. Glia. 2021.

68. Grolez G, Moreau C, Daniel-Brunaud V, Delaire C, Lopes R, Pradat PF, et al. The value of magnetic resonance imaging as a biomarker for amyotrophic lateral sclerosis: a systematic review. BMC Neurol. 2016;16:155.

69. Ravits JM, La Spada AR. ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology. 2009;73:805–11.

70. Stroman PW, Wheeler-Kingshott C, Mason, Schwab JM, Bosma R, Brooks J, et al. The current state-of-the-art of spinal cord imaging: methods. NeuroImage. 2014;84:1070–81.

71. Verma T, Cohen-Adad J. Effect of respiration on the B0 field in the human spinal cord at 3T. Magn Reson Med. 2014;72:1629–36.

72. Wallhout R, Westeneng H-J, Verstraete E, Hendrikse J, Veldink JH, van den Heuvel MP, et al. Cortical thickness in ALS: towards a marker for upper motor neuron involvement. J Neurol Neurosurg Psychiatry. 2015;86:288–94.

73. Sage CA, Peeters RR, Gorner A, Robberecht W, Sunaert S. Quantitative diffusion tensor imaging in amyotrophic lateral sclerosis. NeuroImage. 2007;34:486–99.

74. Gatto RG, Weissmann C, Amin M, Finkielstein A, Sumagin R, Mareci TH, et al. Assessing neuraxial microstructural changes in a transgenic mouse model of early stage amyotrophic lateral sclerosis by ultra-high field MRI and diffusion tensor metrics. Animal Model Exp Med. 2020;3:117–29.

75. Adachi Y, Sato N, Saito Y, Kimura Y, Nakata Y, Ito K, et al. Usefulness of SWI for the detection of iron in the motor cortex in amyotrophic lateral sclerosis. J Neuroimag. 2015;25:443–51.

76. Meadowcroft MD, Mutic NJ, Bigler DC, Wang J-L, Simmons Z, Connor JR, et al. Histological-MRI correlation in the primary motor cortex of patients with amyotrophic lateral sclerosis. J Magn Reson Imaging. 2015;41:665–75.

77. Kwan JY, Jeong SY, Van Gelderen P, Deng H-X, Quezado MM, Danielian LE, et al. Iron accumulation in deep cortical layers accounts for MRI signal abnormalities in ALS: correlating 7 tesla MRI and pathology. PLOS ONE. 2012;7:e52451.

78. Nairz M, Theurl I, Swirski FK, Weiss G. “Pumping iron”–how macrophages handle iron at the systemic, microenvironmental, and cellular levels. Pflugers Arch. 2017;469(3–4):397–418.

79. Sako W, Izumi Y, Abe T, Haji S, Murakami N, Osaki Y, et al. MR spectroscopy and imaging-derived measurements in the supplementary motor area for biomarkers of amyotrophic lateral sclerosis. Neuro Sci. 2021.

80. Dai Z, Chen Y, Yan G, Gang xiao, Shen Z, Wu R. Gang xiao, Zhiwei Shen, Renhua Wu. Progress of magnetic resonance imaging in amyotrophic lateral sclerosis. Radiol Infect Dis. 2019;6:1–7.

81. Alam MM, Lee J, Lee SY. Recent progress in the development of TSPO PET ligands for neuroinflammation imaging in neurological diseases. Nucl Med Mol Imaging. 2017;51:283–96.
83. Block W, Karitzky J, Träber F, Pohl C, Keller E, Mundegar RR, et al. Proton magnetic resonance spectroscopy of the primary motor cortex in patients with motor neuron disease: subgroup analysis and follow-up measurements. Arch Neurol. 1998;55:931–6.

84. Bowen BC, Pattany PM, Bradley WG, Murdoch JB, Rotta F, Younis AA, et al. MR imaging and localized proton spectroscopy of the precentral gyrus in amyotrophic lateral sclerosis. Am J Neuroradiol. 2000;21:647–58.

85. Benatar M, Boylan K, Jeromin A, Rutkove SB, Berry J, Atassi N, et al. ALS biomarkers for therapy development: state of the field and future directions. Muscle Nerve. 2016;53:169–82.

86. Benatar M, Zhang L, Wang L, Granit V, Stalolland J, Barohn R, et al. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology. 2020;95:e59–69.

87. Oeckl P, Jardel C, Salachas F, Lamari F, Andersen PM, Bowser R, et al. Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS. Amyotroph Lateral Scler Frontotemp Degen. 2016;17(5–6):404–13.

88. Lu C-H, Macdonald-Wallis C, Gray E, Pearce N, Petzold A, Norgren N, et al. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015;84:2247–57.

89. Lu C-H, Petzold A, Topping JO, Allen K, Macdonald-Wallis C, Clarke J, et al. Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study. J Neurol Neurosurg Psychiatry. 2015;86:565–73.

90. Devos D, Moreau C, Kyheng M, Garçon G, Rolland AS, Blasco H, et al. A ferroptosis-based panel of prognostic biomarkers for Amyotrophic Lateral Sclerosis. Sci Rep. 2019;9:2918.

91. Swindell WR, Kruse CPS, List EO, Berryman DE, Kopchick JJ. ALS blood expression profiling identifies new biomarkers, patient subgroups, and evidence for neutrophilia and hypoxia. J Transl Med. 2019;17:170.

92. Winer L, Srinivasan D, Chum S, Lacomics D, Jaffa M, Fagan A, et al. SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy. JAMA Neurol. 2013;70:201–7.

93. Mitchell RM, Freeman WM, Randazzo WT, Stephens HE, Beard JL, Simmons Z, et al. A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis. Neurology. 2009;72:14–9.

94. Oeckl P, Weydt P, Steinacker P, Anderl-Straub S, Nordin F, Volk AE, et al. Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase. J Neurol Neurosurg Psychiatry. 2019;90:4–10.

95. Vuk L, An J, Kovalik T, Gendron T, Petrucelli L, Bowser R. Cross-sectional and longitudinal measures of chitinase proteins in amyotrophic lateral sclerosis and expression of CHI3L1 in activated astrocytes. J Neurol Neurosurg Psychiatry. 2020;91:350–8.

96. Gray E, Thompson AG, Wuu J, Pelt J, Talbot K, Benatar M, et al. CSF chitinases before and after symptom onset in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2020;7:1296–306.

97. Shephard SR, Wuu J, Cardoso M, Wiklendt L, Dinning PG, Chataway T, et al. Urinary p75(ECD): A prognostic, disease progression, and pharmacodynamic biomarker in ALS. Neurology. 2017;88:1137–43.

98. Lee DH, Claussen GC, Oh S. Clinical nerve conduction and needle electromyography studies. J Am Acad Orthop Surg. 2004;12:276–87.

99. Yi C, Cui X, Kim S, Wians R, Sorge R, Oh SJ, et al. Smads as muscle biomarkers in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2014;1:778–87.

100. Tasca E, Pegoraro V, Merico A, Angelini C. Circulating microRNAs as biomarkers of muscle differentiation and atrophy in ALS. Clin Neurophysiol. 2016;35:22–30.

101. Chio A, Calvo A, Bovio G, Canosa A, Bertuzzo D, Galmozzi F, et al. Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study. JAMA Neurol. 2014;71:1134–42.

102. Offen D, Halevi S, Orion D, Mosberg R, Stern-Goldberg H, Melamed E, et al. Antibodies from ALS patients inhibit dopamine release mediated by L-type calcium channels. Neurology. 1998;51:1100–3.

103. Fischer LR, Culver DG, Tennant P, Davis AA, Wang M, Castellano-Sanchez A, et al. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol. 2004;185:232–40.

104. Pagani MR, Gonzalez LE, Uchitel OD. Autoimmunity in amyotrophic lateral sclerosis: past and present. Neurol Res Int. 2011;2011:497080.

105. Yi F-H, Lautrette C, Vermot-Desroches C, Bordessoule D, Couratier P, Wijdenes J, et al. In vitro induction of neuronal apoptosis by anti-Fas antibody-containing sera from amyotrophic lateral sclerosis patients. J Neuroimmunol. 2000;109:211–20.

106. Ordonez G, Sotelo J. Antibodies against fetal muscle proteins in serum from patients with amyotrophic lateral sclerosis. Neurology. 1989;39:683–6.

107. Pestronk A, Adams RN, Clawson L, Cornblath D, Kuncel RW, Griffin D, et al. Serum antibodies to GM1 ganglioside in amyotrophic lateral sclerosis. Neurology. 1988;38:1457–61.

108. Niebroj-Dobosz J, Janik P, Kwiecinski H. Serum IgM anti-GM1 ganglioside antibodies in lower motor neuron syndromes. Eur J Neurol. 2004;11:13–6.

109. Couratier P, Yi F-H, Freud’homme J-L, Clavelou P, White A, Sindou P, et al. Serum autoantibodies to neurofilament proteins in sporadic amyotrophic lateral sclerosis. J Neurol Sci. 1998;154:137–45.

110. Fialová L, Švarcová J, Bartos A, Kallay P, Malbohan I, Keller O, et al. Cerebrospinal fluid and serum antibodies against neurofilaments in patients with amyotrophic lateral sclerosis. Eur J Neurol. 2010;17:562–6.

111. Puentes F, Topping J, Kuhle J, van der Stor B, Douriri A, Giovannoni G, et al. Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2013;84:274–8.

112. Okuyama Y, Mizuno T, Inoue H, Kimoto K. Amyotrophic lateral sclerosis with anti-acetylcholine receptor antibody. Intern Med. 1997;36:312–5.

113. Alexianu ME, Kozovska M, Appel SH. Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology. 2001;57:1282–9.

114. Chiu IM, Phatnani H, Kuligowski M, Tapia JC, Carrasco MA, Zhang M, et al. Activation of innate and humoral immunity in the peripheral nervous system of ALS transgenic mice. Proc Natl Acad Sci USA. 2009;106:20960–5.
115. Gruber DJ, Hickey WF, Harris BT. Progressive changes in microglia and macrophages in spinal cord and peripheral nerve in the transgenic rat model of amyotrophic lateral sclerosis. J Neuroinflammation. 2010;7:8.

116. Troost D, Das PK, van den Oord JJ, Louwse ES. Immunohistochemical alterations in muscle of patients with amyotrophic lateral sclerosis: mononuclear cell phenotypes and expression of MHC products. Clin Neuropathol. 1992;11:115–20.

117. Graves M, Fiela M, Dingslan LA, Liu N, Sayre J, Chiappelli F, et al. Inflammation in amyotrophic lateral sclerosis spinal cord and brain is mediated by activated macrophages, mast cells and T cells. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5:213–9.

118. Troost D, Van den Oord JJ, Vianney de Jong JM. Neuroinflammation, Engelhardt JI, Tajti J, Appel SH. Lymphocytic infiltrates in amyotrophic lateral sclerosis: a study of virus antibodies and lymphocyte subsets. Acta Neurol Scand. 1988;78:449–54.

119. Consilvio C, Vincent AM, Feldman EL. Neuroinflammation, COX-2, and ALS—a dual role? Exp Neurol. 2004;187:1–10.

120. Henkel JS, Engelhardt JI, Siklós L, Simpson EP, Kim SH, Pan T, et al. Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann Neurol. 2004;55:221–35.

121. Hensley K, Abdel-Moaty H, Hunter J, Mhatre M, Mou S, Nguyen K, et al. Primary glia expressing the G93A-SOD1 mutation present a neuroinflammatory phenotype and provide a cellular system for studies of glial inflammation. J Neuroinflammation. 2006;3:2.

122. Engelhardt JI, Tajti J, Appel SH. Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis. Arch Neurol. 1993;50:30–6.

123. Saresella M, Piancone F, Tortorella P, Marventano I, Gatti A, Caputo D, et al. T helper-17 activation dominates the immunologic milieu of both amyotrophic lateral sclerosis and progressive multiple sclerosis. Clin Immunol. 2013;148:79–88.

124. Troost D, van den Oord JJ, de Jong JM, Swaab DF. Lymphocytic infiltration in the spinal cord of patients with amyotrophic lateral sclerosis. Clin Neuropathol. 1989;8:85–94.

125. Calvo A, Moglia C, Balma M, Chio A. Involvement of immune response in the pathogenesis of amyotrophic lateral sclerosis: a therapeutic opportunity? CNS Neurol Drug Treat Targets. 2010;9:325–30.

126. Rentzos M, Evangelopoulos E, Sereti E, Zouvelou V, Marmara S, Alexakis T, et al. Alterations of T cell subsets in ALS: a systemic immune activation? Acta Neurol Scand. 2011;125:260–4.

127. Italiani P, Carlesi C, Giungato P, Puxeddu I, Borroni B, Bossù P, et al. Evaluating the levels of interleukin-1 family cytokines in sporadic amyotrophic lateral sclerosis. J Neuroinflammation. 2014;11:94.

128. Rentzos M, Nikolaou C, Rombos A, Boufidou F, Zoga M, Dimitrakopoulos A, et al. RANTES levels are elevated in serum and cerebrospinal fluid in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2007;8:283–7.

129. Liu G-T, Hwang C-S, Hsieh C-H, Lu C-H, Chang S-Y, Lee J-C, et al. Eosinophil-derived neurotoxin is elevated in patients with amyotrophic lateral sclerosis. Mediators Inflamm. 2013;2013:421389.

130. Ono S, Hu J, Shimizu N, Imai T, Nakagawa H. Increased interleukin-6 of skin and serum in amyotrophic lateral sclerosis. J Neurol Sci. 2001;187:27–34.

131. Rentzos M, Nikolaou C, Rombos A, Boufidou F, Zoga M, Dimitrakopoulos A, et al. RANTES levels are elevated in serum and cerebrospinal fluid in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2007;8:283–7.

132. Bahia El IdriSSI N, Bosch S, Ramaglia V, Aronica E, Baas F, Troost D. Complement activation at the motor end-plates in amyotrophic lateral sclerosis. J Neuroinflamm. 2016;13:72.

133. Uschitani M, Shimohama S. The role of nitric oxide in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001;2:71–81.

134. Hensley K, Mhatre M, Mou S, Pye QN, Stewart C, West M, et al. On the relation of oxidative stress to neuroinflammation: lessons learned from the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. Antioxid Redox Signal. 2006;8:2075–87.

135. Kawamata T, Akiyama H, Yamada T, McGeer PL. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am J Pathol. 1992;140:691–707.

136. Mohamed HA, Mosier DR, Zou LL, Siklós L, Alexianu ME, Engelhardt JI, et al. Immunoglobulin Fc gamma receptor promotes immunoglobulin uptake, immunoglobulin-mediated calcium increase, and neurotransmitter release in motor neurons. J Neurosci Res. 2002;69:110–6.

137. Coque E, Salsac C, Espinosa-Carrasco G, Varga B, Degauque N, Cadoux M, et al. Cytotoxic CD8(+) T lymphocytes expressing ALS-causing SOD1 mutant selectively trigger death of spinal motoneurons. Proc Natl Acad Sci USA. 2011;116:2312–7.

138. Murdock BJ, Goutman SA, Boss J, Kim S, Feldman EL. Amyotrophic lateral sclerosis survival associates with neutrophils in a sex-specific manner. Neurol Neuroimmun inflammon. 2021;8:e953.

139. Chiarotto GB, Nardo G, Trolese MC, Franca MC Jr, Bendotti C, Rodrigues de Oliveira AL. The emerging role of the major histocompatibility complex class I in amyotrophic lateral sclerosis. Int J Mol Sci. 2017;18:2298.

140. Schoser BG, Wehling S, Blottner D. Cell death and apoptosis-related proteins in muscle biopsies of sporadic amyotrophic lateral sclerosis and polyneuropathy. Muscle Nerve. 2001;24:1083–9.

141. Takahashi H, Noto Y-I, Makita N, Kushimura-Okada Y, Ishii R, Tanaka A, et al. Myasthenic symptoms in anti-low-density lipoprotein receptor-related protein 4 antibody-seropositive amyotrophic lateral sclerosis: two case reports. BMC Neurol. 2016;16:229.

How to cite this article: Amor S, Nutma E, Marzin M, Puentes F. Imaging immunological processes from blood to brain in amyotrophic lateral sclerosis. Clin Exp Immunol. 2021;206:301–313. https://doi.org/10.1111/cei.13660